Dyadic International Receives $3M Grant to Develop Antibodies for RSV, Malaria

TipRanks11minutes ago

Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology

Reuters22minutes ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

GlobeNewswire22minutes ago

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript Summary

moomoo AINov 16 21:07 ET · Conference Call

Express News | HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target

BenzingaNov 14 05:56 ET

Dyadic International Reports Q3 2024 Growth and Strategic Advances

TipRanksNov 12 23:15 ET